1
00:00:02,000 --> 00:00:04,384
Two peptides. Two complementary pathways.

2
00:00:04,384 --> 00:00:08,674
One combination. CagriSema brings cagrilintide and semaglutide together, without

3
00:00:08,674 --> 00:00:11,535
turning them into a single molecule.

4
00:00:11,885 --> 00:00:16,277
Developed by Novo Nordisk in Denmark, its clinical story

5
00:00:16,277 --> 00:00:20,668
includes Julio Frias and colleagues' phase two study, published

6
00:00:20,668 --> 00:00:22,132
in twenty twenty-three.

7
00:00:22,132 --> 00:00:26,524
Ninety-two adults with type two diabetes were followed for

8
00:00:26,524 --> 00:00:27,500
thirty-two weeks.

9
00:00:27,850 --> 00:00:30,167
Semaglutide activates GLP-1 receptors.

10
00:00:30,167 --> 00:00:33,642
Cagrilintide engages amylin and calcitonin receptors.

11
00:00:33,642 --> 00:00:37,696
Their complementary signals influence appetite and fullness.

12
00:00:37,696 --> 00:00:42,908
Combining two medicines is different from engineering one peptide

13
00:00:42,908 --> 00:00:45,224
to activate several receptors.

14
00:00:45,574 --> 00:00:49,271
The larger REDEFINE 1 trial followed three thousand four

15
00:00:49,271 --> 00:00:52,967
hundred and seventeen adults without type two diabetes for

16
00:00:52,967 --> 00:00:56,663
sixty-eight weeks. Published in the New England Journal of

17
00:00:56,663 --> 00:01:00,359
Medicine in twenty twenty-five, it tested the combination, each

18
00:01:00,359 --> 00:01:01,591
component, and placebo.

19
00:01:01,941 --> 00:01:06,096
Estimated average weight reduction was twenty point four percent

20
00:01:06,096 --> 00:01:10,250
with the combination, versus three percent with placebo, regardless

21
00:01:10,250 --> 00:01:11,635
of treatment adherence.

22
00:01:11,635 --> 00:01:15,790
A separate analysis assuming adherence gave twenty-two point seven

23
00:01:15,790 --> 00:01:18,560
percent. Those estimates answer different questions.

24
00:01:18,910 --> 00:01:22,961
Nausea, vomiting, diarrhea and constipation were reported.

25
00:01:22,961 --> 00:01:28,171
And in twenty twenty-six, a direct comparison with tirzepatide

26
00:01:28,171 --> 00:01:31,643
did not meet its non-inferiority target.

27
00:01:31,643 --> 00:01:36,274
Greater complexity does not automatically mean better results.

28
00:01:36,624 --> 00:01:41,161
As of October thirteen, twenty twenty-six, Novo still describes

29
00:01:41,161 --> 00:01:42,673
CagriSema as investigational.

30
00:01:42,673 --> 00:01:47,210
Research programmes address obesity and type two diabetes, with

31
00:01:47,210 --> 00:01:49,227
different populations and endpoints.

32
00:01:49,227 --> 00:01:53,764
Its promise rests on evidence, not the number of

33
00:01:53,764 --> 00:01:54,268
ingredients.

34
00:01:55,000 --> 00:01:56,300
Peptides in 2.

35
00:01:56,300 --> 00:01:57,600
World Peptide Foundation.

36
00:01:57,820 --> 00:01:59,399
Every experience matters.